Phase I study of the ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehyde-thiosemicarbazone (3-AP) in combination with high dose cytarabine in patients with advanced myeloid leukemia
Olatoyosi M. Odenike, Richard A. Larson, Devika Gajria, M. Eileen Dolan, Shannon M. Delaney, Theodore G. Karrison, Mark J. Ratain, Wendy StockVolume:
26
Langue:
english
Pages:
7
DOI:
10.1007/s10637-008-9115-6
Date:
June, 2008
Fichier:
PDF, 138 KB
english, 2008